Aug 6 (Reuters) - Novavax ( NVAX ) beat Wall Street
expectations for second-quarter revenue on Wednesday, helped by
a $175 million milestone payment related to U.S. approval of its
COVID-19 vaccine in May.
The biotech reported total revenue of $239 million, compared
with analysts' average estimate of $147.96 million, according to
data compiled by LSEG.